137 related articles for article (PubMed ID: 27726177)
1. Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.
Hoashi T; Hirabayashi M; Nakajima R; Takahashi N; Saeki H
J Dermatol; 2017 Sep; 44(9):1078-1079. PubMed ID: 27726177
[No Abstract] [Full Text] [Related]
2. Angiosarcoma of the scalp successfully treated with pazopanib.
Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A
J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520
[No Abstract] [Full Text] [Related]
3. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
Kitamura S; Hata H; Imafuku K; Haga N; Homma E; Shimizu H
Clin Exp Dermatol; 2015 Dec; 40(8):931-3. PubMed ID: 25817046
[No Abstract] [Full Text] [Related]
4. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
Miura H; Shirai H
Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
[No Abstract] [Full Text] [Related]
5. Enterocolitis: An Unknown Side Effect of Pazopanib.
Sharma A; Masood U; Manocha D
Am J Ther; 2017; 24(4):e490-e491. PubMed ID: 27574944
[No Abstract] [Full Text] [Related]
6. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
[No Abstract] [Full Text] [Related]
7. Pazopanib-Associated Transient Ischemic Attack.
Revuelta-Herrero JL; Escudero-Vilaplana V; Álvarez-Álvarez R; Sanjurjo-Sáez M
Am J Ther; 2018; 25(3):e393-e394. PubMed ID: 29424756
[No Abstract] [Full Text] [Related]
8. Angiosarcoma of the scalp responding to nivolumab: a case report.
Hofer S; Zeidler K; Schipf A; Kempf W; Zimmermann D; Aebi S
Br J Dermatol; 2018 Aug; 179(2):530-531. PubMed ID: 29700818
[No Abstract] [Full Text] [Related]
9. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
10. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Ono S; Tanioka M; Fujisawa A; Tanizaki H; Miyachi Y; Matsumura Y
Arch Dermatol; 2012 Jun; 148(6):683-5. PubMed ID: 22710450
[No Abstract] [Full Text] [Related]
11. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
12. Angiosarcoma of the scalp treated with OK-432 and rIL-2.
Miura H; Inui S; Sakai H; Hasebe N; Itami S; Yoshikawa K
Int J Dermatol; 2002 May; 41(5):286-8. PubMed ID: 12100706
[No Abstract] [Full Text] [Related]
13. A case of advanced scalp angiosarcoma successfully treated with combination chemotherapy of adriamycin, cisplatin and ifosfamide.
Kanat O; Ozet A; Ataergin SA; Arpaci F; Ozturk B; Arpaci F; Ozturk M; Komurcu S; Kuzhan O
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426-7. PubMed ID: 16817336
[No Abstract] [Full Text] [Related]
14. Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib.
Fujiwara S; Nagai H; Nakamachi Y; Kawano S; Nishigori C
Eur J Dermatol; 2015; 25(1):71-3. PubMed ID: 25679339
[No Abstract] [Full Text] [Related]
15. Unresectable angiosarcoma treated with bevacizumab and paclitaxel.
Nespereira-Jato MV; Peña-Panabad C; Quindós-Varela M; García-Silva J
Actas Dermosifiliogr; 2014 Jun; 105(5):520-2. PubMed ID: 24144236
[No Abstract] [Full Text] [Related]
16. A case of cutaneous angiosarcoma successfully treated with eribulin.
Iwamoto K; Fujisawa Y; Ishitsuka Y; Maruyama H; Nakamura Y; Okiyama N; Watanabe R; Fujimoto M
Eur J Dermatol; 2018 Jun; 28(3):410-412. PubMed ID: 29619993
[No Abstract] [Full Text] [Related]
17. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T
Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262
[No Abstract] [Full Text] [Related]
18. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
Ravi V; Sanford EM; Wang WL; Ross JS; Ramesh N; Futreal A; Patel S; Stephens PJ; Miller VA; Ali SM
J Natl Compr Canc Netw; 2016 May; 14(5):499-502. PubMed ID: 27160228
[TBL] [Abstract][Full Text] [Related]
20. Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Donghi D; Dummer R; Cozzio A
Br J Dermatol; 2010 Mar; 162(3):697-9. PubMed ID: 20030640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
